Financial PositionWith a strong balance sheet and significant catalysts expected, a favorable view of the PHVS story is maintained.
Product ExpansionPharvaris is advancing deucrictibant for the treatment of hereditary angioedema, with potential expansion beyond HAE Type 1/2.
Regulatory ProgressManagement recently announced receipt of Thorough QT (TQT) waivers, which apply to the prophylactic program for deucrictibant extended-release formulation and the on-demand program for deucrictibant immediate-release formulation.